Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Helsinki University Central Hospital | OTHER |
| Turku University Hospital | OTHER_GOV |
| Tampere University Hospital | OTHER |
| Oulu University Hospital |
Not provided
Not provided
Not provided
The purpose of this study is to find out if sacral neuromodulation is an effective treatment for pelvic pain associated with surgically treated endometriosis.
Endometriosis is typically associated with severe pelvic pain and pain is often combined with dysfunctional symptoms of the urinary bladder and the bowel. Endometriosis impairs the health-related quality of life and pain is the main reason for the decreased quality of life. When the primary endometriosis treatments, i.e. hormonal therapy and surgery, fail to alleviate pain or symptoms recur after successful treatment, the options are often limited. Recurrent or long-lasting endometriosis pain commonly involves neuropathic pain component with periferal or central sensitisation to pain. This kind of pain is likely more resistant to traditional endometriosis treatments and thus neuromodulation offers a logical treatment option.
There are some case series and at least one randomized trial describing the effect of Sacral Neuromodulation in chronic pelvic pain associated with interstitial cystitis and painful bladder syndrome. These reports indicate that Sacral Neuromodulation may be effective in treating chronic pelvic pain but the level of evidence is low. There is one report on long-term pelvic pain with Visual Analogue Scale score dropping from 8.1 to 2.1 and the effect lasting for five years. There are also few case reports on different difficult sacral area pain conditions treated successfully with Sacral Nerve Modulation. The common consensus seems to be that further studies are needed on the effects of Sacral Neuromodulation on chronic pelvic pain.
This study aims to evaluate if sacral neuromodulation alleviates pelvic pain symptoms and related dysfunctional symptoms in surgically treated endometriosis patients and improves their health-related quality of life. The treating gynecologist does the screening for suitable patients and a signed informed consent is needed from the patients prior to entering the study. A test pulse generator is placed uni- or bilaterally under local or general anesthesia and used during a 2-3-week test period. A permanent pulse generator is placed if marked improvement of symptoms is detected, the patient is satisfied with the treatment and willing to continue. Women not responding to sacral neuromodulation will not receive a permanent generator. They are asked to continue in the 3 year follow-up and they serve as the control group if applicable.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sacral neuromodulation | Other | The purpose of this study is to find out if Sacral Neuromodulation is an effective treatment for pelvic pain associated with endometriosis. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Sacral Neuromodulation | Device | S3 nerve root (sometimes S4) is stimulated with low electrical current via an electrode placed through a sacral foramen. This electrode is connected to a stimulator resembling a cardiac pacemaker. |
| Measure | Description | Time Frame |
|---|---|---|
| Pelvic pain intensity and frequency | Pain is evaluated with Patient's pain diary: self-reported daily pain intensity (NRS 0-10) for dysmenorrhea, non-cyclic pelvic pain, dyschezia, dysuria and dyspareunia during one month period. NRS= numerical rating scale with 0 meaning "no pain" and 10 meaning "Worst pain one can imagine" | Change measures at baseline, before and during Sacral neuromodulation test period and 1-2 months after initiation of the modulation and then every 6 months for 3 years |
| Measure | Description | Time Frame |
|---|---|---|
| Pelvic pain intensity | Pain is evaluated with Brief Pain Inventory Questionnaire at clinical visits | Change measures at baseline, before and during Sacral neuromodulation test period and 1-2 months after initiation of the modulation and then every 6 months for 3 years |
| Disease specific health-related quality of life |
| Measure | Description | Time Frame |
|---|---|---|
| The need for sick-leave due to pelvic pain/endometriosis | Number of sick-leave days/week during 6 months period | Change measures: retrospectively asked at baseline and then every 6 months during the 3 year follow-up |
Inclusion Criteria:
Exclusion Criteria:
gender identity
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Adrian Zegrea | Contact | +35864153405 | adrian.zegrea@epshp.fi | |
| Tarja Pinta | Contact | tarja.pinta@epshp.fi |
| Name | Affiliation | Role |
|---|---|---|
| Teuvo Tammela | Tampere University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Turku University Hospital (Tyks) Main Hospital | Recruiting | Turku | Southwest Finland | 20521 | Finland |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D004715 | Endometriosis |
| ID | Term |
|---|---|
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
Not provided
Not provided
| OTHER |
| Jyväskylä Central Hospital | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
|
Endometriosis Health Profile Questionnaire (EHP-30) |
| Change measures at baseline, before and during Sacral neuromodulation test period and 1-2 months after initiation of the modulation and then every 6 months for 3 years |
| General health-related Quality of life | 15D-measure | Change measures at baseline, before and during Sacral neuromodulation test period and 1-2 months after initiation of the modulation and then every 6 months for 3 years |
| Sexual health-related quality of life | McCoy Female Sexuality Questionaire | Change measures at baseline, before and during Sacral neuromodulation test period and 1-2 months after initiation of the modulation and then every 6 months for 3 years |
| Pelvic organ dysfunction symptoms | Pelvic Floor Distress Inventory (PFDI-20) | Change measures at baseline, before and during Sacral neuromodulation test period and 1-2 months after initiation of the modulation and then every 6 months for 3 years |
| Patient satisfaction with sacral neuromodulation treatment | Evaluation of satisfaction with sacral neuromodulation treatment evaluated with NRS 0-10 (0= totally dissatisfied and 10= totally satisfied) | Change measures 1-2 months after initiation of the sacral neuromodulation and then every 6 months for 3 years |
| D000091662 | Genital Diseases |